Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726734 | 0.89 | TSHR (0.58) | ALDH1A1TSHRKDM4EGLAGAA | |
| Oxalic Acid SCHEMBL29685154 | 0.84 | TSHR (0.55) | ALDH1A1TSHRKDM4EGLAGAA | |
| SCHEMBL6250266 | 0.84 | CA1 (0.50) | ALDH1A1TSHRKDM4ECA1CA2 | |
| Sulfuric Acid SCHEMBL29684657 | 0.83 | TSHR (0.53) | ALDH1A1TSHRKDM4ECA1GLA | |
| SCHEMBL28231556 | 0.82 | TSHR (0.56) | ALDH1A1TSHRKDM4ECA1GLA | |
| SCHEMBL29684786 | 0.80 | TSHR (0.50) | ALDH1A1TSHRKDM4EGLAGAA | |
| SCHEMBL14562932 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4EGLAGAA | |
| SCHEMBL4405073 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4EGLAGAA | |
| SCHEMBL1819502 | 0.79 | TSHR (0.49) | ALDH1A1TSHRKDM4ECA1GLA | |
| SCHEMBL10504633 | 0.79 | KDM4E (0.52) | ALDH1A1TSHRKDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014165746-A1 | METHODS AND COMPOSITIONS USING ADAM10 INHIBITORS TO TREAT BACTERIAL INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | ALDH1A1 1158/4885TSHR 4092/4885KDM4E 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.